| |
TechnoVax
- Patented approach to create single and multi-valent influenza VLP vaccines
- Patented scalable mammalian cell-based system to continuously produce VLP vaccine in shorter time and at reduced costs
- Licensed system allows for VLP vaccine development for other respiratory virus targets (e.g. RSV, PIV and metapneumovirus) on
co-exclusive bases with licensor, Wyeth
- Additional patent applications protect the VLP system for developing vaccines for respiratory viruses
- Able to significantly improve the technology, because we are the inventor of this VLP vaccine development system
|
|
VLP Competition
- One competitor that uses this VLP system for developing only mono-valent influenza vaccines
- Competition uses the insect cell system, which requires two steps and production is limited to 72hs; then the process has to be repeated
- Competiton not allowed to use this VLP system for developing vaccines against the specified respiratory targets
- Further preclude competiton of using this VLP system to develop vaccine for respiratory viruses ( RSV, PIV, metapneumovirus)
- Limit competiton’s ability to utilize the VLP system
|
|
|
Presentación en Español